Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
23 - Indirect Central Nervous System Effects of Botulinum Toxin
from Section II - Botulinum Toxin Therapy
Published online by Cambridge University Press: 31 May 2018
Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Treatment of Dystonia , pp. 106 - 110Publisher: Cambridge University PressPrint publication year: 2018
References
Aoki, KR (2005). Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicol 26:785–793.Google Scholar
Byrnes, ML, Thickbroom, GW, Wilson, SA, Sacco, P, Shipman, JM, Stell, R (1998). The corticomotor representation of upper limb muscles in writer’s cramp and changes following botulinum toxin injection. Brain 121:977–988.Google Scholar
Caleo, M, Antonucci, F, Restani, L, Mazzocchio, R (2009). A re-appraisal of the central effects of botulinum toxin type A: by what mechanism? J Neurochem 109: 15–24.CrossRefGoogle Scholar
Ce, P (2000). Central effects of botulinum toxin: study of brainstem auditory evoked potentials. Eur J Neurol 7: 747.CrossRefGoogle ScholarPubMed
Ceballos-Baumann, AO, Sheean, G, Passingham, RE, Marsden, CD, Brooks, DJ (1997). Botulinum toxin does not reverse the cortical dysfunction associated with writer’s cramp: a PET study. Brain 120:571–582.CrossRefGoogle Scholar
Conte, A, Fabbrini, G, Belvisi, D, Marsili, K, Di Stasio, F, Berardelli, A (2010). Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm. Eur J Neurol 17:449–455.CrossRefGoogle Scholar
Eleopra, R, Tugnoli, V, De Grandis, D, Montecucco, C (1998). Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256: 135–138.CrossRefGoogle Scholar
Fascarelli, F, Di Rosa, G, Bisozzi, E, Castelli, E, Santilli, V (2011). Neurophysiological changes induced by the botulinum toxin type A injection in children with cerebral palsy. Eur J Paediat Neurol 15: 59–64.CrossRefGoogle Scholar
Habermann, E (1974). 125I labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptomoses and ascent to spinal cord. Naunyn Schmiedebergs Arch Pharmacol 281: 47–56.CrossRefGoogle ScholarPubMed
Hagenah, R, Bebecke, R, Wiegand, H (1977). Effect of type A botulinum toxin on the cholinergic transmission at the spinal Renshaw cells and on the inhibitory action at Ia inhibitory interneurons. Arch Pharmal 299: 267–272.CrossRefGoogle Scholar
Hamjian, JA, Walker, F (1994). Serial neurophysiological studies of intramuscular botulinum-A toxins in human. Muscle Nerve 17: 1385–1392.CrossRefGoogle Scholar
Kaji, R, Rosako, Y, Suyama, K, Maeda, T, Uechi, Y, Iwasaki, M (2010). Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 26:1983–1992.CrossRefGoogle ScholarPubMed
Kanovský, P, Rosales, RL (2011). Debunking the pathophysiological puzzle of dystonia: with special reference to botulinum toxin therapy. Parkinsonism Relat Disord 17: S11–S14.CrossRefGoogle ScholarPubMed
Kim, DY, Oh, BM, Paik, NJ (2006). Central effect of botulinum toxin A in humans. Int J Neurosci 116(6): 667–680.Google Scholar
Kojovic, M, Caronni, A, Bologna, M, Bhatia, K, Rothwell, J, Edwards, M (2011). Botulinum toxin injections reduce associative plasticity in patients with primary dystonia. Movement Disord 26(7): 1282–1289.CrossRefGoogle ScholarPubMed
Naumann, M, Reiners, R (1997). Long-latency reflexes of hand muscles in idiopathic focal dystonia and their modification by botulinum toxin. Brain 120: 409–416.CrossRefGoogle ScholarPubMed
Palomar, F, Mir, P (2012). Neurophysiological changes after intramuscular injection of botulinum toxin. Clinic Neurophysiol 123: 54–60.CrossRefGoogle ScholarPubMed
Picelli, A, Lobba, D, Midiri, A, Prandi, P, Melotti, C, Baldessarelli, S, Smania, N (2014). Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques. Clin Rehabil 28(3): 232–242.CrossRefGoogle ScholarPubMed
Pickett, A, Rosales, RL (2011). New trends in the science of botulinum toxin-A as applied in dystonia. Int J Neurosci 121: 22–34.CrossRefGoogle ScholarPubMed
Pierrot-Deseilligny, E, Burke, D. (2005). The Circuitry of the Human Spinal Cord: Its Role in Motor Control and Movement Disorders. Cambridge: Cambridge University Press.CrossRefGoogle Scholar
Priori, A, Berardelli, A, Mercuri, B, Manfredi, M (1995). Physiological effects produced by botulinum toxin treatment of upper limb dystonia: changes in reciprocal inhibition between forearm muscles. Brain 118:801–807.CrossRefGoogle ScholarPubMed
Rosales, RL (2012). Dystonia, spasticity and botulinum toxin therapy: rationale, evidences and clinical context. In: Rosales, RL (Ed.), Dystonia: The Many Facets. Croatia: Intech Open Access Publishers.CrossRefGoogle Scholar
Rosales, RL, Dressler, D (2010). On muscle spindles, dystonia and botulinum toxin. Eur J Neurol 17 (Suppl. 1): 71–80.CrossRefGoogle ScholarPubMed
Rosales, RL, Arimura, K, Takenaga, S, Osame, M (1996). Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19: 488–496.3.0.CO;2-8>CrossRefGoogle ScholarPubMed
Rosales, RL, Dressler, D, Bigalke, H (2006). Pharmacologic differences between botulinum toxins. Eur J Neurol 13: 2–10.CrossRefGoogle Scholar
Rosales, RL, Delos Santos, MM, Ng, AR, Teleg, R, Dantes, M, Lee, LV, Fernandez, HH (2011a). The broadening application of chemodenervation in X-linked dystonia-parkinsonism (part I): muscle afferent block versus botulinum toxin-A in cervical and limb dystonias. Int J Neurosci 121: 35–43.CrossRefGoogle ScholarPubMed
Rosales, RL, Kanovsky, P, Fernandez, HH (2011b). What’s the ‘catch’ in upper-limb post-stroke spasticity: expanding the role of botulinum toxin applications. Parkinsonism Relat Disord 17: S3–S10.CrossRefGoogle ScholarPubMed
Rosales, RL, Kong, KH, Goh, KJ, Kumthornthip, W, Mok, VCT, Delgado-De Los Santos, MM, Chua, KSG, Abdullah, SJF, Zakine, B, Maisonob, P, Magis, A, Wong, KSL (2012). Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair 26(7): 812–821.CrossRefGoogle ScholarPubMed
Senkarova, Z, Hlustik, P, Otruba, P, Herzig, R, Kanovsky, P (2010). Modulation of cortical activity in patients suffering from upper arm spasticity following stroke and treated with botulinum toxin A: an fMRI study. J Neuroimaging 20: 9–15.CrossRefGoogle ScholarPubMed
Ward, SR, Lieber, RL (2009). Biological and mechanical pathologies in spastic skeletal muscle: the functional implications of therapeutic toxins. In: Jankovic, J (Ed.), Botulinum Toxin: Therapeutic Clinical Practice and Science. Philadelphia, PA: Saunders.Google Scholar
Wohlfarth, K, Schubert, M, Rothe, B, Elek, J, Dengler, R (2001). Remote F-wave changes after local botulinum toxin application. Clin Neurophysiol 112: 636–640.CrossRefGoogle ScholarPubMed
Yamada, N, Kakuda, W, Kondo, T, Mitani, S, Shimizu, M, Abo, M (2014). Local muscle injection of botulinum toxin type A synergistically improves the beneficial effects of repetitive transcranial magnetic stimulation and intensive occupational therapy in post-stroke patients with spastic upper limb hemiparesis. Eur Neurol 72: 290–298.CrossRefGoogle ScholarPubMed
Zeuner, KE, Knutzen, A, Al-Ali, A, Hallett, M, Deuschl, G, Bergmann, TO (2010). Associative stimulation of the supraorbital nerve fails to induce timing-specific plasticity in the human blink reflex. PLoS One 5:13602–13614.CrossRefGoogle ScholarPubMed
- 1
- Cited by